| Autor: |
Yanxiao Gao, Weiran Zheng, Yinghui Sun, Luoyao Yang, Zhihui Guo, Yuwei Li, Yi-Fan Lin, Zhen Lu, Tanwei Yuan, Yuewei Zhan, Han-Zhu Qian, Bin Su, Zhiqiang Zhu, Junyi Duan, Guanghui Wang, Xin Cui, Lin Ouyang, Genshen Sheng, Yepeng Zhou, Ao Long, Yuming Yao, Thomas Fitzpatrick, Maohe Yu, Guohui Wu, Huachun Zou |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
JMIR Research Protocols, Vol 12, p e47160 (2023) |
| Druh dokumentu: |
article |
| ISSN: |
1929-0748 |
| DOI: |
10.2196/47160 |
| Popis: |
BackgroundSystematic reviews and meta-analyses based on observational studies have shown voluntary medical male circumcision (VMMC) may reduce HIV risk among men who have sex with men (MSM). There is a lack of randomized controlled trial (RCT) data assessing the efficacy of VMMC. ObjectiveThe primary objective of this study is to assess the efficacy of VMMC for preventing HIV acquisition among MSM who primarily engage in insertive anal sex. MethodsA multicenter RCT will be conducted among MSM in 8 cities in China. Eligible participants are men aged 18-49 years who self-report ≥2 male sex partners in the past 6 months, predominantly practice insertive anal sex, and are willing to undergo circumcision. Interested men who satisfy inclusion criteria will be tested for HIV 1 month before enrollment and at enrollment, and only those who are HIV negative will be enrolled. At baseline, all enrolled participants will be asked to report sociodemographic characteristics and sexual behaviors; provide a blood sample for HIV, syphilis, and herpes simplex virus type 2 testing; and provide a penile swab for human papillomavirus testing. Participants will be randomly assigned to the intervention or control group. Those in the intervention group will receive VMMC and undergo a web-based weekly follow-up assessment of postsurgery healing for 6 consecutive weeks. All participants will be tested for HIV at 3-, 6-, 9-, and 12-month follow-ups. All participants will also be asked to report sexual behaviors and undergo repeat herpes simplex virus type 2 and human papillomavirus testing at 6- and 12-month follow-ups. The primary end point is HIV seroconversion. Secondary end points are the safety and satisfaction with VMMC and the changes in sexual behaviors after VMMC. The grouped censored data will be analyzed by intention-to-treat approach. ResultsRecruitment for the RCT began in August 2020 and continued through July 2022. Data collection is expected to be completed by July 2023, and full data analysis is going to be completed by September 2023. ConclusionsThis study will be the first RCT to assess the efficacy of VMMC in preventing HIV infection among MSM. Results from this trial will provide preliminary evidence for the potential efficacy of VMMC to reduce incident HIV infection among MSM. Trial RegistrationChinese Clinical Trial Registry ChiCTR2000039436; https://www.chictr.org.cn/showproj.html?proj=63369 International Registered Report Identifier (IRRID)DERR1-10.2196/47160 |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
